Format

Send to

Choose Destination
Cell Death Dis. 2018 May 1;9(5):439. doi: 10.1038/s41419-018-0463-7.

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.

Author information

1
Department of Oncology and Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet, SE-17176, Stockholm, Sweden.
2
Department of Oncology and Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet, SE-17176, Stockholm, Sweden. Klas.Wiman@ki.se.
3
Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, SE-17177, Stockholm, Sweden.

Abstract

The TP53 tumor suppressor gene is frequently inactivated in human tumors by missense mutations in the DNA binding domain. TP53 mutations lead to protein unfolding, decreased thermostability and loss of DNA binding and transcription factor function. Pharmacological targeting of mutant p53 to restore its tumor suppressor function is a promising strategy for cancer therapy. The mutant p53 reactivating compound APR-246 (PRIMA-1Met) has been successfully tested in a phase I/IIa clinical trial. APR-246 is converted to the reactive electrophile methylene quinuclidinone (MQ), which binds covalently to p53 core domain. We identified cysteine 277 as a prime binding target for MQ in p53. Cys277 is also essential for MQ-mediated thermostabilization of wild-type, R175H and R273H mutant p53, while both Cys124 and Cys277 are required for APR-246-mediated functional restoration of R175H mutant p53 in living tumor cells. These findings may open opportunities for rational design of novel mutant p53-targeting compounds.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center